Revenue · FY 2026
₹28,163 Cr
▲ 2.23% YoY
EBITDA · FY 2026
₹6,764.91 Cr
▼ 15.33% YoY
Net profit · FY 2026
₹3,861.74 Cr
▼ 26.71% YoY
Authorised capital
₹175 Cr
Registered with MCA
Paid-up capital
₹161.56 Cr
Issued & subscribed
Open charges
None
Satisfied ₹68.5 Cr
Company age
91 yrs
Est. 1935
Employees · EPFO
25,952
Latest available
About Cipla Limited
Data last updated: 18 March 2026
Cipla Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 17 August 1935, the company has been in operation for over 91 years.
Registered with ROC Mumbai under CIN L24239MH1935PLC002380. Listed on BSE: 500087 and NSE: CIPLA.
Capital: an authorised share capital of ₹175 Cr and a paid-up capital of ₹161.56 Cr. Formerly known as The Chemical Industrial and Pharmaceutical Laboratories Limited. It is led by directors including Kamil Hamied and Yusuf Hamied Khwaja.
Last AGM: 16 July 2025. Financial statements filed for year ended 31 March 2025. Office: Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013.
As per the financials filed for FY 2025, the company reported a revenue of ₹28,409 Cr, a growth of 7% compared to the previous year.
The company has a workforce of approximately 25,952 employees as per the latest available data. Its group structure includes 9 subsidiaries.
The company is associated with 3 brands - Ciplamed, Mirren, Cipla. As per MCA filings, the company has satisfied charges of ₹68.5 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cipla.com.
Company Details of Cipla Limited
CIN
L24239MH1935PLC002380
Registration Number
002380
Incorporation Date
17 August 1935
ROC
Mumbai
Listing Status
Listed (BSE: 500087, NSE: CIPLA)
Company Status
Active
Date of Last AGM
16 July 2025
Date of Balance Sheet
31 March 2025
Compliance Status
Active Compliant
Contact Details
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressCipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013
-
IndustryPharma, API Manufacturers, Drug Formulation & Development
Company report
Cipla Limited - full intelligence report
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
₹799
₹999
20% off
Secure checkout · GST invoice included
Associated Brands with Cipla Limited
Cipla Limited operates multiple associated brands including Ciplamed, Mirren, and Cipla. These brands represent Cipla Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers online medical news, guidelines, and educational content for professionals. | ciplamed.com | |
| Natural gas assets are developed alongside innovative pipeline solutions. | mirren.co.za | |
| APIs, generic drugs, and formulation services are manufactured. | cipla.com |
Competitors & Alternatives of Cipla Limited
Brands and companies operating in the same space as Cipla Limited include OpenEvidence, Nested Knowledge, QxMD and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
OpenEvidence
|
Medical evidence is aggregated and visualized for healthcare professionals. | Cambridge, United States, United States | 2021 |
Nested Knowledge
|
Clinical evidence platform provided for pharma, device, and research entities. | Saint Paul, United States, United States | 2018 |
QxMD
|
Point-of-care digital tools are developed for healthcare professionals. | Vancouver, Canada, Canada | 2006 |
Emerson Ecologics
|
Medicines, supplements, and healthcare products are supplied online. | Manchester, United States, United States | 1998 |
Copient Health
|
Predictive analysis solutions are provided for healthcare providers. | Alpharetta, United States, United States | 2019 |
EMedicine
|
Medical reference information is published online for healthcare professionals. | New York, United States, United States | 1996 |
The Clinics
|
App offering clinical resources | Maryland Heights, United States, United States | 1999 |
iDoctus
|
Medical app providing drug searches, interactions, and clinical tools for healthcare professionals. | Spain, United States, United States | 2011 |
Business Activity of Cipla Limited
Cipla Limited is engaged in principal business activities including manufacturing and trade, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Cipla Limited
Cipla Limited is audited by Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Cipla Limited
Cipla Limited is currently managed by 13 directors, with 38 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Kamil Hamied
Also directs:
Alps Remedies Private Limited, Famid Sports Private Limited
|
Director | 01 Nov 2024 | 1 Years 8 Months | Current |
|
Yusuf Hamied Khwaja
Also directs:
Famid Sports Private Limited
|
Director | 21 Jul 1972 | 53 Years 11 Months | Current |
|
Ramesh Prathivadibhayankara Rajagopalan
Also directs:
Nestle India Limited, Crompton Greaves Consumer Electricals Limited, Itc Hotels Limited and 5 more
|
Director | 01 Jul 2021 | 5 Years 0 Months | Current |
| Abhijit Jagdish Joshi | Director | 03 Sep 2024 | 1 Years 10 Months | Current |
|
Umang Vohra
Also directs:
Cipla Health Limited, Stempeutics Research Private Limited
|
Managing Director | 01 Sep 2016 | 9 Years 10 Months | Current |
|
Sharmila Nitin Paranjpe
Also directs:
Door Step School Foundation
|
Director | 01 Sep 2024 | 1 Years 10 Months | Current |
Showing 6 of 13 current directors. View all directors
Financials of Cipla Limited FY 2026 filings available
Cipla Limited reported revenue of ₹28,163 Cr (up 2.23% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
Revenue · FY 2026
₹28,163 Cr
▲ 2.23%
Profit · FY 2026
₹3,861.74 Cr
▼ 26.71%
EBITDA · FY 2026
₹6,764.91 Cr
▼ 15.33%
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹28,163 Cr | ₹27,548 Cr | ₹25,774 Cr | ₹22,753 Cr | ₹21,763 Cr | ₹19,160 Cr | ₹17,132 Cr |
| Other Income | ₹882.01 Cr | ₹861.87 Cr | ₹746.57 Cr | ₹475.45 Cr | ₹280.91 Cr | ₹265.99 Cr | ₹344.2 Cr |
| Total Income | ₹29,045 Cr | ₹28,409 Cr | ₹26,521 Cr | ₹23,229 Cr | ₹22,044 Cr | ₹19,426 Cr | ₹17,476 Cr |
| Cost of Materials Consumed | ₹5,841.62 Cr | ₹5,409.6 Cr | ₹5,220.51 Cr | ₹5,519.62 Cr | ₹5,533.13 Cr | ₹4,886.43 Cr | ₹4,376.81 Cr |
| Purchases of Stock-in-Trade | ₹4,451.37 Cr | ₹3,851.49 Cr | ₹3,536.03 Cr | ₹2,828.66 Cr | ₹3,687.16 Cr | ₹2,658.17 Cr | ₹1,859.37 Cr |
| Changes in Inventories | -₹743.88 Cr | -₹332.1 Cr | ₹63.03 Cr | -₹96 Cr | -₹724.69 Cr | -₹192.71 Cr | -₹244.76 Cr |
| Employee Benefit Expense | ₹5,366.33 Cr | ₹4,832.83 Cr | ₹4,310.04 Cr | ₹3,830.08 Cr | ₹3,529.91 Cr | ₹3,251.83 Cr | ₹3,027.01 Cr |
| Finance Costs | ₹54.39 Cr | ₹62.01 Cr | ₹89.88 Cr | ₹109.54 Cr | ₹106.35 Cr | ₹160.7 Cr | ₹197.36 Cr |
| Depreciation & Amortisation | ₹1,210.98 Cr | ₹1,106.95 Cr | ₹1,051.02 Cr | ₹1,172.11 Cr | ₹1,051.95 Cr | ₹1,067.66 Cr | ₹1,174.65 Cr |
| Other Expenses | ₹7,364.25 Cr | ₹6,657.9 Cr | ₹6,353.43 Cr | ₹5,643.79 Cr | ₹5,185.05 Cr | ₹4,303.44 Cr | ₹4,907.57 Cr |
| Total Expenses | ₹23,545 Cr | ₹21,589 Cr | ₹20,624 Cr | ₹19,008 Cr | ₹18,369 Cr | ₹16,136 Cr | ₹15,298 Cr |
| Profit Before Exceptional Items & Tax | ₹5,499.54 Cr | ₹6,820.81 Cr | ₹5,896.72 Cr | ₹4,220.77 Cr | ₹3,675.39 Cr | ₹3,290.06 Cr | ₹2,178.18 Cr |
| Exceptional Items | -₹275.91 Cr | ₹0 | -₹194.82 Cr | -₹182.42 Cr | -₹182.12 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹5,223.63 Cr | ₹6,820.81 Cr | ₹5,701.9 Cr | ₹4,038.35 Cr | ₹3,493.27 Cr | ₹3,290.06 Cr | ₹2,178.18 Cr |
| Total Tax Expense | ₹1,353.84 Cr | ₹1,529.76 Cr | ₹1,546.59 Cr | ₹1,202.86 Cr | ₹933.8 Cr | ₹888.76 Cr | ₹631.2 Cr |
| Net Profit | ₹3,861.74 Cr | ₹5,269.2 Cr | ₹4,153.72 Cr | ₹2,832.89 Cr | ₹2,546.65 Cr | ₹2,388.51 Cr | ₹1,499.52 Cr |
| attributable to Owners | ₹3,879.23 Cr | ₹5,272.52 Cr | ₹4,121.55 Cr | ₹2,801.91 Cr | ₹2,516.75 Cr | ₹2,404.87 Cr | ₹1,546.52 Cr |
| attributable to NCI | -₹17.49 Cr | -₹3.32 Cr | ₹32.17 Cr | ₹30.98 Cr | ₹29.9 Cr | -₹16.36 Cr | -₹47 Cr |
| Other Comprehensive Income | ₹687.74 Cr | ₹218.66 Cr | -₹120.58 Cr | ₹137.63 Cr | ₹383.67 Cr | ₹161.49 Cr | -₹129.4 Cr |
| Total Comprehensive Income | ₹4,549.48 Cr | ₹5,487.86 Cr | ₹4,033.14 Cr | ₹2,970.52 Cr | ₹2,930.32 Cr | ₹2,550 Cr | ₹1,370.12 Cr |
| EBITDA (computed) | ₹6,764.91 Cr | ₹7,989.77 Cr | ₹7,037.62 Cr | ₹5,502.42 Cr | ₹4,833.69 Cr | ₹4,518.42 Cr | ₹3,550.19 Cr |
| Basic EPS | ₹48.03 | ₹65.29 | ₹51.05 | ₹34.72 | ₹31.20 | ₹29.82 | ₹19.19 |
| Diluted EPS | ₹48.00 | ₹65.24 | ₹51.01 | ₹34.69 | ₹31.17 | ₹29.79 | ₹19.16 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹42,496 Cr | ₹37,387 Cr | ₹32,718 Cr | ₹29,463 Cr |
| Non-current Assets | ₹18,349 Cr | ₹14,099 Cr | ₹13,276 Cr | ₹12,188 Cr |
| Current Assets | ₹24,146 Cr | ₹23,249 Cr | ₹19,392 Cr | ₹16,805 Cr |
| Property, Plant & Equipment | ₹6,039.8 Cr | ₹5,262.26 Cr | ₹5,068.97 Cr | ₹4,990.78 Cr |
| Inventories | ₹6,596.72 Cr | ₹5,642.11 Cr | ₹5,237.95 Cr | ₹5,156.43 Cr |
| Trade Receivables | ₹5,620.05 Cr | ₹5,506.37 Cr | ₹4,770.66 Cr | ₹4,057 Cr |
| Cash & Equivalents | ₹1,018.22 Cr | ₹588.69 Cr | ₹640.07 Cr | ₹627.63 Cr |
| Equity (Net Worth) | ₹34,520 Cr | ₹31,289 Cr | ₹26,802 Cr | ₹23,714 Cr |
| Equity Share Capital | ₹161.56 Cr | ₹161.52 Cr | ₹161.47 Cr | ₹161.43 Cr |
| Borrowings (Non-current) | ₹117.47 Cr | ₹11.98 Cr | ₹0 | ₹0 |
| Borrowings (Current) | ₹140.5 Cr | ₹80.12 Cr | ₹247.02 Cr | ₹520.36 Cr |
| Total Debt (computed) | ₹257.97 Cr | ₹92.1 Cr | ₹247.02 Cr | ₹520.36 Cr |
| Current Liabilities | ₹7,013.59 Cr | ₹5,483.96 Cr | ₹5,245.77 Cr | ₹5,033.27 Cr |
| Total Liabilities | ₹7,975.74 Cr | ₹6,097.79 Cr | ₹5,915.49 Cr | ₹5,749.74 Cr |
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹3,940.02 Cr | ₹5,004.98 Cr | ₹4,133.91 Cr | ₹3,237.65 Cr | ₹3,325.9 Cr |
| Investing Cash Flow | -₹2,326.13 Cr | -₹3,691.14 Cr | -₹2,988.03 Cr | -₹2,388.51 Cr | -₹1,871.88 Cr |
| Financing Cash Flow | -₹1,233.65 Cr | -₹1,292.79 Cr | -₹1,200.43 Cr | -₹958.29 Cr | -₹1,599.79 Cr |
| Capital Expenditure | ₹1,599.33 Cr | ₹1,162.16 Cr | ₹1,098.25 Cr | ₹840.53 Cr | ₹544.11 Cr |
| Free Cash Flow (computed) | ₹2,340.69 Cr | ₹3,842.82 Cr | ₹3,035.66 Cr | ₹2,397.12 Cr | ₹2,781.79 Cr |
| Dividends Paid | ₹1,292.4 Cr | ₹1,049.83 Cr | ₹686.17 Cr | ₹403.5 Cr | ₹403.35 Cr |
| Net Change in Cash | ₹472.74 Cr | ₹30.31 Cr | -₹48.99 Cr | -₹96.78 Cr | -₹132.32 Cr |
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹6,541.2 Cr | ₹7,074.48 Cr | ₹7,589.44 Cr | ₹6,957.47 Cr | ₹6,729.69 Cr | ₹7,072.97 Cr | ₹7,051.02 Cr | ₹6,693.94 Cr | ₹6,163.24 Cr | ₹6,603.81 Cr | ₹6,678.15 Cr | ₹6,328.89 Cr |
| Other Income | ₹148.16 Cr | ₹206.34 Cr | ₹268.95 Cr | ₹258.56 Cr | ₹289.46 Cr | ₹221.61 Cr | ₹190.61 Cr | ₹160.19 Cr | ₹249.33 Cr | ₹184.63 Cr | ₹176.32 Cr | ₹136.29 Cr |
| Total Income | ₹6,689.36 Cr | ₹7,280.82 Cr | ₹7,858.39 Cr | ₹7,216.03 Cr | ₹7,019.15 Cr | ₹7,294.58 Cr | ₹7,241.63 Cr | ₹6,854.13 Cr | ₹6,412.57 Cr | ₹6,788.44 Cr | ₹6,854.47 Cr | ₹6,465.18 Cr |
| Cost of Materials Consumed | ₹1,382.15 Cr | ₹1,461.96 Cr | ₹1,528.16 Cr | ₹1,469.35 Cr | ₹1,397.94 Cr | ₹1,296.73 Cr | ₹1,474.03 Cr | ₹1,240.9 Cr | ₹1,252.69 Cr | ₹1,196.18 Cr | ₹1,472.66 Cr | ₹1,298.98 Cr |
| Purchases of Stock-in-Trade | ₹1,284.73 Cr | ₹1,248.64 Cr | ₹892.98 Cr | ₹1,025.02 Cr | ₹1,023.68 Cr | ₹913.23 Cr | ₹814.59 Cr | ₹1,099.99 Cr | ₹738.96 Cr | ₹927.21 Cr | ₹890.19 Cr | ₹979.67 Cr |
| Changes in Inventories | -₹418.2 Cr | -₹78.52 Cr | ₹76.5 Cr | -₹323.66 Cr | -₹232.6 Cr | ₹54.12 Cr | -₹5.61 Cr | -₹148.01 Cr | ₹58.47 Cr | ₹96.14 Cr | -₹49.76 Cr | -₹41.82 Cr |
| Employee Benefit Expense | ₹1,414.25 Cr | ₹1,324.98 Cr | ₹1,314.8 Cr | ₹1,312.3 Cr | ₹1,233.1 Cr | ₹1,197.62 Cr | ₹1,207.88 Cr | ₹1,194.23 Cr | ₹1,084.23 Cr | ₹1,068.13 Cr | ₹1,091.1 Cr | ₹1,066.58 Cr |
| Finance Costs | ₹13.13 Cr | ₹14.03 Cr | ₹13.18 Cr | ₹14.05 Cr | ₹14.02 Cr | ₹14.64 Cr | ₹15.4 Cr | ₹17.95 Cr | ₹17.59 Cr | ₹30.1 Cr | ₹25.8 Cr | ₹16.39 Cr |
| Depreciation & Amortisation | ₹382.92 Cr | ₹278.35 Cr | ₹296.99 Cr | ₹252.72 Cr | ₹308.73 Cr | ₹279.8 Cr | ₹271.74 Cr | ₹246.68 Cr | ₹288.34 Cr | ₹233.43 Cr | ₹290.04 Cr | ₹239.21 Cr |
| Other Expenses | ₹1,923.32 Cr | ₹1,862.36 Cr | ₹1,882.25 Cr | ₹1,696.32 Cr | ₹1,769.98 Cr | ₹1,622.35 Cr | ₹1,674.54 Cr | ₹1,591.03 Cr | ₹1,713.03 Cr | ₹1,568.62 Cr | ₹1,540.21 Cr | ₹1,531.57 Cr |
| Total Expenses | ₹5,982.3 Cr | ₹6,111.8 Cr | ₹6,004.86 Cr | ₹5,446.1 Cr | ₹5,514.85 Cr | ₹5,378.49 Cr | ₹5,452.57 Cr | ₹5,242.77 Cr | ₹5,153.31 Cr | ₹5,119.81 Cr | ₹5,260.24 Cr | ₹5,090.58 Cr |
| Profit Before Exceptional Items & Tax | ₹707.06 Cr | ₹1,169.02 Cr | ₹1,853.53 Cr | ₹1,769.93 Cr | ₹1,504.3 Cr | ₹1,916.09 Cr | ₹1,789.06 Cr | ₹1,611.36 Cr | ₹1,259.26 Cr | ₹1,668.63 Cr | ₹1,594.23 Cr | ₹1,374.6 Cr |
| Exceptional Items | ₹0 | -₹275.91 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹194.82 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹707.06 Cr | ₹893.11 Cr | ₹1,853.53 Cr | ₹1,769.93 Cr | ₹1,504.3 Cr | ₹1,916.09 Cr | ₹1,789.06 Cr | ₹1,611.36 Cr | ₹1,259.26 Cr | ₹1,473.81 Cr | ₹1,594.23 Cr | ₹1,374.6 Cr |
| Total Tax Expense | ₹156.95 Cr | ₹218.55 Cr | ₹500.46 Cr | ₹477.88 Cr | ₹279.28 Cr | ₹332.37 Cr | ₹483.04 Cr | ₹435.07 Cr | ₹324.86 Cr | ₹405.3 Cr | ₹438.41 Cr | ₹378.02 Cr |
| Net Profit | ₹542.51 Cr | ₹674.25 Cr | ₹1,353.37 Cr | ₹1,291.61 Cr | ₹1,214.14 Cr | ₹1,574.59 Cr | ₹1,305.01 Cr | ₹1,175.46 Cr | ₹931.87 Cr | ₹1,068.41 Cr | ₹1,155.37 Cr | ₹998.07 Cr |
| attributable to Owners | ₹554.64 Cr | ₹675.8 Cr | ₹1,351.17 Cr | ₹1,297.62 Cr | ₹1,221.84 Cr | ₹1,570.51 Cr | ₹1,302.53 Cr | ₹1,177.64 Cr | ₹939.04 Cr | ₹1,055.9 Cr | ₹1,130.91 Cr | ₹995.7 Cr |
| attributable to NCI | -₹12.13 Cr | -₹1.55 Cr | ₹2.2 Cr | -₹6.01 Cr | -₹7.7 Cr | ₹4.08 Cr | ₹2.48 Cr | -₹2.18 Cr | -₹7.17 Cr | ₹12.51 Cr | ₹24.46 Cr | ₹2.37 Cr |
| Other Comprehensive Income | ₹135.79 Cr | ₹204.11 Cr | ₹266.43 Cr | ₹81.41 Cr | ₹54.46 Cr | -₹37.71 Cr | ₹131.17 Cr | ₹70.74 Cr | -₹79.48 Cr | ₹2.41 Cr | ₹64.26 Cr | -₹107.77 Cr |
| Total Comprehensive Income | ₹678.3 Cr | ₹878.36 Cr | ₹1,619.8 Cr | ₹1,373.02 Cr | ₹1,268.6 Cr | ₹1,536.88 Cr | ₹1,436.18 Cr | ₹1,246.2 Cr | ₹852.39 Cr | ₹1,070.82 Cr | ₹1,219.63 Cr | ₹890.3 Cr |
| EBITDA (computed) | ₹1,103.11 Cr | ₹1,461.4 Cr | ₹2,163.7 Cr | ₹2,036.7 Cr | ₹1,827.05 Cr | ₹2,210.53 Cr | ₹2,076.2 Cr | ₹1,875.99 Cr | ₹1,565.19 Cr | ₹1,932.16 Cr | ₹1,910.07 Cr | ₹1,630.2 Cr |
| Basic EPS | ₹6.87 | ₹8.37 | ₹16.73 | ₹16.07 | ₹15.13 | ₹19.45 | ₹16.13 | ₹14.58 | ₹11.63 | ₹13.08 | ₹14.01 | ₹12.34 |
| Diluted EPS | ₹6.86 | ₹8.36 | ₹16.72 | ₹16.06 | ₹15.12 | ₹19.43 | ₹16.12 | ₹14.57 | ₹11.62 | ₹13.07 | ₹14.00 | ₹12.33 |
Latest 12 quarters shown of 24 on record.
| Segment · Q3 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹6,746.4 Cr | ₹1,122.26 Cr | ₹0 | ₹0 |
| New ventures | ₹381.48 Cr | ₹60.79 Cr | ₹0 | ₹0 |
| Segment · FY 2025 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceuticals | ₹26,446 Cr | ₹6,872.29 Cr | - | - |
| New ventures | ₹1,303.36 Cr | ₹10.53 Cr | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹18,980 Cr | ₹19,045 Cr | ₹16,574 Cr | ₹15,791 Cr | ₹13,092 Cr | ₹13,901 Cr | ₹12,659 Cr |
| Other Income | ₹1,122.65 Cr | ₹984.72 Cr | ₹1,070.66 Cr | ₹456.79 Cr | ₹666.7 Cr | ₹230.28 Cr | ₹892.85 Cr |
| Total Income | ₹20,103 Cr | ₹20,030 Cr | ₹17,645 Cr | ₹16,247 Cr | ₹13,758 Cr | ₹14,131 Cr | ₹13,552 Cr |
| Cost of Materials Consumed | ₹3,992.34 Cr | ₹3,642.84 Cr | ₹2,617.21 Cr | ₹3,502.77 Cr | ₹2,767.79 Cr | ₹3,262.29 Cr | ₹2,999.17 Cr |
| Purchases of Stock-in-Trade | ₹2,587.97 Cr | ₹2,056.75 Cr | ₹2,360.41 Cr | ₹1,993.39 Cr | ₹2,850.85 Cr | ₹1,847.85 Cr | ₹1,363.12 Cr |
| Changes in Inventories | -₹596.45 Cr | -₹229.87 Cr | ₹104.57 Cr | ₹205.26 Cr | -₹528.4 Cr | -₹9.93 Cr | -₹43.08 Cr |
| Employee Benefit Expense | ₹3,350.48 Cr | ₹3,054.87 Cr | ₹2,644.21 Cr | ₹2,377.27 Cr | ₹1,729.16 Cr | ₹2,038.88 Cr | ₹1,911.08 Cr |
| Finance Costs | ₹19.3 Cr | ₹15.11 Cr | ₹20.25 Cr | ₹27.02 Cr | ₹26.93 Cr | ₹45.07 Cr | ₹36.05 Cr |
| Depreciation & Amortisation | ₹658.43 Cr | ₹573.89 Cr | ₹587.59 Cr | ₹595.91 Cr | ₹460.01 Cr | ₹556.11 Cr | ₹599.78 Cr |
| Other Expenses | ₹5,210.22 Cr | ₹4,741.82 Cr | ₹4,363.79 Cr | ₹3,919.33 Cr | ₹2,905.92 Cr | ₹3,039.93 Cr | ₹3,721.57 Cr |
| Total Expenses | ₹15,222 Cr | ₹13,855 Cr | ₹12,698 Cr | ₹12,621 Cr | ₹10,212 Cr | ₹10,780 Cr | ₹10,588 Cr |
| Profit Before Exceptional Items & Tax | ₹4,880.31 Cr | ₹6,174.16 Cr | ₹4,946.97 Cr | ₹3,626.44 Cr | ₹3,546.23 Cr | ₹3,350.66 Cr | ₹2,964.31 Cr |
| Exceptional Items | -₹244.37 Cr | ₹294.66 Cr | ₹0 | -₹185.9 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹4,635.94 Cr | ₹6,468.82 Cr | ₹4,946.97 Cr | ₹3,440.54 Cr | ₹3,546.23 Cr | ₹3,350.66 Cr | ₹2,964.31 Cr |
| Total Tax Expense | ₹1,120.76 Cr | ₹1,311.17 Cr | ₹1,232.78 Cr | ₹971.01 Cr | ₹856.84 Cr | ₹882.38 Cr | ₹646.14 Cr |
| Net Profit | ₹3,515.18 Cr | ₹5,157.65 Cr | ₹4,077.25 Cr | ₹2,513.47 Cr | ₹2,957.93 Cr | ₹2,468.28 Cr | ₹2,318.17 Cr |
| Other Comprehensive Income | -₹146.3 Cr | -₹9.98 Cr | -₹80.36 Cr | -₹8.97 Cr | ₹6.1 Cr | ₹41.46 Cr | -₹64.43 Cr |
| Total Comprehensive Income | ₹3,368.88 Cr | ₹5,147.67 Cr | ₹3,996.89 Cr | ₹2,504.5 Cr | ₹2,964.03 Cr | ₹2,509.74 Cr | ₹2,253.74 Cr |
| EBITDA (computed) | ₹5,558.04 Cr | ₹6,763.16 Cr | ₹5,554.81 Cr | ₹4,249.37 Cr | ₹4,033.17 Cr | ₹3,951.84 Cr | ₹3,600.14 Cr |
| Basic EPS | ₹43.52 | ₹63.87 | ₹46.01 | ₹30.61 | ₹33.34 | ₹30.61 | ₹28.76 |
| Diluted EPS | ₹43.49 | ₹63.82 | ₹45.97 | ₹30.58 | ₹33.30 | ₹30.57 | ₹28.72 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹38,493 Cr | ₹35,566 Cr | ₹31,053 Cr | ₹27,596 Cr |
| Non-current Assets | ₹20,581 Cr | ₹17,157 Cr | ₹16,146 Cr | ₹14,225 Cr |
| Current Assets | ₹17,912 Cr | ₹18,369 Cr | ₹14,858 Cr | ₹13,371 Cr |
| Property, Plant & Equipment | ₹3,782.45 Cr | ₹3,507.64 Cr | ₹3,370.39 Cr | ₹3,547.83 Cr |
| Inventories | ₹4,353.71 Cr | ₹3,607.12 Cr | ₹3,254.28 Cr | ₹3,277.36 Cr |
| Trade Receivables | ₹3,396.74 Cr | ₹3,859.99 Cr | ₹2,681.75 Cr | ₹2,888.49 Cr |
| Cash & Equivalents | ₹248.8 Cr | ₹82.74 Cr | ₹164.52 Cr | ₹29.48 Cr |
| Equity (Net Worth) | ₹34,201 Cr | ₹32,099 Cr | ₹27,974 Cr | ₹24,638 Cr |
| Equity Share Capital | ₹161.56 Cr | ₹161.52 Cr | ₹161.47 Cr | ₹161.43 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹10.6 Cr | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹10.6 Cr | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹3,871.78 Cr | ₹3,183.42 Cr | ₹2,862.25 Cr | ₹2,699.74 Cr |
| Total Liabilities | ₹4,291.98 Cr | ₹3,466.48 Cr | ₹3,079.31 Cr | ₹2,958.38 Cr |
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹2,831.69 Cr | ₹3,300.99 Cr | ₹3,726.77 Cr | ₹3,035.05 Cr | ₹2,773.43 Cr |
| Investing Cash Flow | -₹1,344.09 Cr | -₹2,308.53 Cr | -₹2,882.82 Cr | -₹2,757.95 Cr | -₹2,463.73 Cr |
| Financing Cash Flow | -₹1,321.9 Cr | -₹1,073.93 Cr | -₹708.83 Cr | -₹424.77 Cr | -₹426.72 Cr |
| Capital Expenditure | ₹780.69 Cr | ₹571.06 Cr | ₹550.49 Cr | ₹586.4 Cr | ₹305.04 Cr |
| Free Cash Flow (computed) | ₹2,051 Cr | ₹2,729.93 Cr | ₹3,176.28 Cr | ₹2,448.65 Cr | ₹2,468.39 Cr |
| Dividends Paid | ₹1,292.4 Cr | ₹1,049.83 Cr | ₹686.17 Cr | ₹403.5 Cr | ₹403.35 Cr |
| Net Change in Cash | ₹166.06 Cr | -₹81.78 Cr | ₹135.04 Cr | -₹147.81 Cr | -₹117.43 Cr |
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹4,209.98 Cr | ₹4,498.08 Cr | ₹5,225.72 Cr | ₹5,046.17 Cr | ₹4,797.89 Cr | ₹4,970.88 Cr | ₹4,775.03 Cr | ₹4,501.05 Cr | ₹4,036.66 Cr | ₹4,381.33 Cr | ₹4,664.72 Cr | ₹4,318.19 Cr |
| Other Income | ₹180.22 Cr | ₹416.7 Cr | ₹254.66 Cr | ₹271.07 Cr | ₹293.37 Cr | ₹188.69 Cr | ₹289.14 Cr | ₹213.52 Cr | ₹538.61 Cr | ₹168.98 Cr | ₹205.09 Cr | ₹157.98 Cr |
| Total Income | ₹4,390.2 Cr | ₹4,914.78 Cr | ₹5,480.38 Cr | ₹5,317.24 Cr | ₹5,091.26 Cr | ₹5,159.57 Cr | ₹5,064.17 Cr | ₹4,714.57 Cr | ₹4,575.27 Cr | ₹4,550.31 Cr | ₹4,869.81 Cr | ₹4,476.17 Cr |
| Cost of Materials Consumed | ₹965.58 Cr | ₹1,003.81 Cr | ₹1,005.18 Cr | ₹1,017.77 Cr | ₹923.6 Cr | ₹940.73 Cr | ₹974.92 Cr | ₹803.59 Cr | ₹517.24 Cr | ₹677.74 Cr | ₹1,001.21 Cr | ₹887.06 Cr |
| Purchases of Stock-in-Trade | ₹763.51 Cr | ₹746.64 Cr | ₹530.39 Cr | ₹547.43 Cr | ₹464.76 Cr | ₹475.64 Cr | ₹544.27 Cr | ₹572.08 Cr | ₹467.43 Cr | ₹537.32 Cr | ₹654.61 Cr | ₹701.05 Cr |
| Changes in Inventories | -₹352.87 Cr | -₹123.68 Cr | ₹23.89 Cr | -₹143.79 Cr | -₹6.75 Cr | -₹44.56 Cr | -₹100.45 Cr | -₹78.11 Cr | ₹176.94 Cr | ₹150.36 Cr | -₹138.74 Cr | -₹133.79 Cr |
| Employee Benefit Expense | ₹869.24 Cr | ₹822.93 Cr | ₹840.01 Cr | ₹818.3 Cr | ₹784.93 Cr | ₹761.45 Cr | ₹744.58 Cr | ₹763.91 Cr | ₹662.15 Cr | ₹648.22 Cr | ₹694.71 Cr | ₹661.83 Cr |
| Finance Costs | ₹6.74 Cr | ₹4.03 Cr | ₹2.65 Cr | ₹5.88 Cr | ₹3.49 Cr | ₹3.55 Cr | ₹3 Cr | ₹5.07 Cr | ₹5.45 Cr | ₹9.06 Cr | ₹7.8 Cr | ₹31 Lakh |
| Depreciation & Amortisation | ₹218.11 Cr | ₹153.33 Cr | ₹141.3 Cr | ₹145.69 Cr | ₹147.7 Cr | ₹142.62 Cr | ₹145.71 Cr | ₹137.86 Cr | ₹136.81 Cr | ₹135.02 Cr | ₹179.81 Cr | ₹135.95 Cr |
| Other Expenses | ₹1,397.41 Cr | ₹1,327.18 Cr | ₹1,303.62 Cr | ₹1,182.01 Cr | ₹1,312.64 Cr | ₹1,175.79 Cr | ₹1,173.67 Cr | ₹1,079.72 Cr | ₹1,385.01 Cr | ₹1,011.83 Cr | ₹1,073.81 Cr | ₹997.35 Cr |
| Total Expenses | ₹3,867.72 Cr | ₹3,934.24 Cr | ₹3,847.04 Cr | ₹3,573.29 Cr | ₹3,630.37 Cr | ₹3,455.22 Cr | ₹3,485.7 Cr | ₹3,284.12 Cr | ₹3,351.03 Cr | ₹3,169.55 Cr | ₹3,473.21 Cr | ₹3,249.76 Cr |
| Profit Before Exceptional Items & Tax | ₹522.48 Cr | ₹980.54 Cr | ₹1,633.34 Cr | ₹1,743.95 Cr | ₹1,460.89 Cr | ₹1,704.35 Cr | ₹1,578.47 Cr | ₹1,430.45 Cr | ₹1,224.24 Cr | ₹1,380.76 Cr | ₹1,396.6 Cr | ₹1,226.41 Cr |
| Exceptional Items | ₹0 | -₹244.37 Cr | ₹0 | ₹0 | ₹294.66 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹522.48 Cr | ₹736.17 Cr | ₹1,633.34 Cr | ₹1,743.95 Cr | ₹1,755.55 Cr | ₹1,704.35 Cr | ₹1,578.47 Cr | ₹1,430.45 Cr | ₹1,224.24 Cr | ₹1,380.76 Cr | ₹1,396.6 Cr | ₹1,226.41 Cr |
| Total Tax Expense | ₹137.84 Cr | ₹119.29 Cr | ₹422.81 Cr | ₹440.82 Cr | ₹270.15 Cr | ₹266.2 Cr | ₹400.31 Cr | ₹374.51 Cr | ₹242.21 Cr | ₹363 Cr | ₹366.91 Cr | ₹331.39 Cr |
| Net Profit | ₹384.64 Cr | ₹616.88 Cr | ₹1,210.53 Cr | ₹1,303.13 Cr | ₹1,485.4 Cr | ₹1,438.15 Cr | ₹1,178.16 Cr | ₹1,055.94 Cr | ₹1,038.4 Cr | ₹1,114.14 Cr | ₹1,029.69 Cr | ₹895.02 Cr |
| Other Comprehensive Income | -₹55.38 Cr | -₹2.6 Cr | -₹84.41 Cr | -₹3.91 Cr | ₹39.37 Cr | -₹10.81 Cr | -₹31.8 Cr | -₹6.74 Cr | -₹65.64 Cr | -₹7.59 Cr | -₹28.25 Cr | ₹21.12 Cr |
| Total Comprehensive Income | ₹329.26 Cr | ₹614.28 Cr | ₹1,126.12 Cr | ₹1,299.22 Cr | ₹1,524.77 Cr | ₹1,427.34 Cr | ₹1,146.36 Cr | ₹1,049.2 Cr | ₹972.76 Cr | ₹1,106.55 Cr | ₹1,001.44 Cr | ₹916.14 Cr |
| EBITDA (computed) | ₹747.33 Cr | ₹1,137.9 Cr | ₹1,777.29 Cr | ₹1,895.52 Cr | ₹1,612.08 Cr | ₹1,850.52 Cr | ₹1,727.18 Cr | ₹1,573.38 Cr | ₹1,366.5 Cr | ₹1,524.84 Cr | ₹1,584.21 Cr | ₹1,362.67 Cr |
| Basic EPS | ₹4.76 | ₹7.64 | ₹14.99 | ₹16.13 | ₹18.39 | ₹17.81 | ₹14.59 | ₹13.08 | ₹12.16 | ₹12.61 | ₹12.76 | ₹11.09 |
| Diluted EPS | ₹4.76 | ₹7.63 | ₹14.98 | ₹16.12 | ₹18.38 | ₹17.79 | ₹14.58 | ₹13.07 | ₹12.15 | ₹12.60 | ₹12.75 | ₹11.08 |
Latest 12 quarters shown of 24 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Cipla Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
Shareholding Pattern of Cipla Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 29.21%, foreign institutional investors hold 22.56%, domestic institutional investors hold 31.97%, retail and other public shareholders hold 16.25% of Cipla Limited. The company had 584,217 shareholders on record.
Mar 2026
QUARTER
29.21% Promoters
31.97% DII (Domestic Institutional)
22.56% FII (Foreign Institutional)
16.25% Retail & Others
Promoter holding - history
Now 29.21% · Mar 2026High 37.57% · Dec 2015Low 29.19% · Dec 2024
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 29.21% | 29.21% | 29.21% | 29.19% | 29.20% | 29.19% |
| Public | 70.79% | 70.79% | 70.79% | 70.81% | 70.80% | 70.81% |
Shareholding history - year on year (as at 31 March)
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 29.21% | 29.20% | 33.47% | 33.55% | 33.63% | 36.73% | 36.68% | 36.70% | 37.21% | 37.48% | 37.50% |
| Public | 70.79% | 70.80% | 66.53% | 66.45% | 66.37% | 63.27% | 63.32% | 63.30% | 62.79% | 62.52% | 62.50% |
| Promoter change (YoY, %pts) | +0.01 | -4.27 | -0.08 | -0.08 | -3.10 | +0.05 | -0.02 | -0.51 | -0.27 | -0.02 | - |
Board & Governance of Cipla Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Cipla Limited has 11 directors - 6 independent and 1 executive. The board is chaired by Y K Hamied.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Y K Hamied | Non-Executive - Non Independent Director · Chairperson | 1972-07-21 | 1 |
| Umang Vohra | Executive Director · CEO-MD | 2016-09-01 | 1 |
| Adil Zainulbhai | Non-Executive - Non Independent Director | 2024-09-03 | 2 |
| Robert Stewart | Non-Executive - Independent Director | 2021-05-14 | 1 |
| Prathivadibhayankara Rajagopalan Ramesh | Non-Executive - Independent Director | 2021-07-01 | 7 |
| Mandar Purushottam Vaidya | Non-Executive - Independent Director | 2022-07-29 | 1 |
| Balram Bhargava | Non-Executive - Independent Director | 2024-04-01 | 1 |
| Sharmila Paranjpe | Non-Executive - Independent Director | 2024-09-01 | 1 |
| Abhijit Jagdish Joshi | Non-Executive - Non Independent Director | 2024-09-03 | 2 |
| Kamil Hamied | Non-Executive - Non Independent Director | 2024-11-01 | 1 |
| Maya Hari | Non-Executive - Independent Director | 2024-11-01 | 1 |
Board Committees
| Committee | Members |
|---|---|
| Audit Committee | Prathivadibhayankara Rajagopalan Ramesh (Chairperson), Balram Bhargava, Sharmila Paranjpe, Maya Hari |
| Nomination and remuneration committee | Mandar Purushottam Vaidya (Chairperson), Adil Zainulbhai, Robert Stewart, Sharmila Paranjpe, Maya Hari, Kamil Hamied |
| Stakeholders Relationship Committee | Mandar Purushottam Vaidya (Chairperson), Adil Zainulbhai, Balram Bhargava |
| Risk Management Committee | Robert Stewart (Chairperson), Umang Vohra, Prathivadibhayankara Rajagopalan Ramesh, Abhijit Jagdish Joshi, Kamil Hamied |
| Corporate Social Responsibility Committee | Balram Bhargava (Chairperson), Adil Zainulbhai, Umang Vohra, Sharmila Paranjpe |
Group Structure of Cipla Limited
Cipla Limited has 9 subsidiary companies and 7 associated companies. This group structure data is as of FY 2025. The corporate group structure reflects Cipla Limited's business expansion strategy and organizational complexity.
9
Subsidiary companies
7
Associated companies
Key Subsidiaries
| Company Name | CIN | Shares Held |
|---|---|---|
| Meditab Specialities Limited | U23240MH1996PLC104442 | - |
| Cipla Health Limited | U24100MH2015PLC267880 | - |
| Goldencross Pharma Limited | U24239MH2000PLC123766 | - |
| Cipla Pharma And Life Sciences Limited | U24239MH2008PLC381559 | - |
| Cipla Pharmaceutical S Limited | U24239MH2019PLC333266 | - |
| Jay Precision Pharmaceutical S Private Limited | U33111MH2012PTC234037 | - |
Showing major subsidiaries. Total: 9.
Charges & Borrowings of Cipla Limited
Open charges
₹0
Satisfied charges
₹68.5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Apr 1986 | The Hongkong and Shanghai Banking Corporation Limited (Lead Charge Holder) | ₹68.5 Cr | Satisfied |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Cipla Limited
Cipla Limited has a workforce of 25,952 employees as of Oct 08, 2025.
Employee count
25,952
Active EPFO establishments
3
Employee growth
4.75%
Employee Count & EPFO Data of Cipla Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification
GST Compliance of Cipla Limited
XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS
GSTIN & GST Filing Data of Cipla Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution
Credit Ratings, Litigation & Regulatory Alerts for Cipla Limited
Credit rating
2015
2017
2019
2021
2023
Litigation
District Court
35
High Court
45
Supreme Court
0
NCLT / NCLAT
0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults
Credit Ratings, Legal Cases & Regulatory Alerts of Cipla Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)
MSME Payment Delays by Cipla Limited
MSME Payment Delays by Cipla Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal
Subsidiaries & Group Companies of Cipla Limited
Subsidiaries & Group Companies of Cipla Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Cipla Limited with ownership details.
Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year
MCA Filings & Documents of Cipla Limited
MCA Filings & Documents of Cipla Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates
Recent Activity on Cipla Limited
Activity
16 Jul 2025
Cipla Limited last Annual general meeting of members was held on 16 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Cipla Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Directors
01 Nov 2024
Kamil Hamied was appointed as a Director on 01 Nov 2024 & has been associated with this company since 1 year 8 months.
Directors
01 Nov 2024
Maya Hari was appointed as a Director on 01 Nov 2024 & has been associated with this company since 1 year 8 months.
Directors
03 Sep 2024
Abhijit Jagdish Joshi was appointed as a Director on 03 Sep 2024 & has been associated with this company since 1 year 10 months.
Directors
01 Sep 2024
Sharmila Nitin Paranjpe was appointed as a Director on 01 Sep 2024 & has been associated with this company since 1 year 10 months.
Recent News on Cipla Limited
Frequently Asked Questions about Cipla Limited
Cipla Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 17 August 1935 (91+ years old) and is registered under CIN L24239MH1935PLC002380. Listed on BSE: 500087 and NSE: CIPLA. The company has 25,952 employees.
Cipla Limited reported revenue of ₹28,409 Cr for FY 2025 (up 7.00% YoY).
The current directors of Cipla Limited are:
The primary industry of Cipla Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Cipla Limited is listed on both BSE (code: 500087) and NSE (symbol: CIPLA).
Cipla Limited can be reached at the registered office: Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013, or through the website cipla.com.